Ferroptosis has become one of the most closely watched topics in cancer biology. Unlike apoptosis, which quietly dismantles a cell in orderly fragments, ferroptosis is a catastrophic collapse of the cell membrane. It begins when lipid peroxides, generated by iron-catalyzed reactions, accumulate beyond the capacity of cellular antioxidant systems such as glutathione. The membrane disintegrates, mitochondria shrink, and the cell bursts in a process that neighboring immune cells can detect. Because many conventional chemotherapies rely on apoptosis, which tumors routinely learn to evade, researchers have hoped that deliberately triggering ferroptosis could offer a way to kill cancer cells that have outsmarted standard treatments.

The new study began with a clinical question rather than a mechanistic one. Using transcriptomic sequencing of hepatocellular carcinoma specimens collected from patients, alongside data from The Cancer Genome Atlas and the Genotype-Tissue Expression project, the researchers found that CDCA5 is markedly upregulated in liver tumor tissue compared with healthy liver. Higher levels correlated with advanced clinicopathological features and poorer prognosis. Pan-cancer analyses extended the picture across tumor types, linking CDCA5 expression to genomic instability, DNA repair signatures, epigenetic features, immune infiltration patterns, and drug-response profiles, though the authors emphasize that these population-level correlations are primarily descriptive rather than proof of causation.

To test whether CDCA5 actually drives malignant behavior, the team performed gain- and loss-of-function experiments in liver cancer cell lines. When they silenced CDCA5 using short hairpin RNA, the cells lost their ability to proliferate, migrate, and invade. Cell-cycle analysis revealed that depletion of the protein pushed cells into G2/M arrest, halting division at a critical checkpoint. Apoptosis assays and colony-formation tests confirmed the loss of tumorigenic capacity. Conversely, forcing CDCA5 overexpression produced the opposite phenotype, accelerating proliferation and invasion. In mouse xenograft models, tumors lacking CDCA5 grew significantly more slowly than controls, providing in vivo evidence that the protein is not merely a passenger mutation but an active promoter of tumor growth.

The mechanistic twist came when the researchers examined how CDCA5-expressing cells respond to ferroptotic stress. Using C11-BODIPY lipid peroxidation staining, malondialdehyde measurements, reactive oxygen species assays, glutathione quantification, mitochondrial activity tests, and iron measurements, they found that depleting CDCA5 increased every hallmark of ferroptosis: lipid peroxides accumulated, ROS rose, glutathione fell, mitochondria malfunctioned, and intracellular Fe2+ climbed. When the team applied ferroptosis inhibitors, these changes were reversed, confirming that the cell death observed was specifically ferroptotic rather than apoptotic or necrotic.

To trace the signaling route, the researchers turned to proteomic analysis and pharmacological perturbation. They discovered that CDCA5 promotes the expression of PP2Ac, the catalytic subunit of Protein Phosphatase 2A. PP2Ac, in turn, reduces the phosphorylation of p53, the well-known tumor suppressor that normally activates ferroptotic programs. With p53 held in a dephosphorylated, less active state, the transcription of STEAP3, a p53-dependent gene involved in iron metabolism, drops. The result is a tumor cell that is less sensitive to iron-driven membrane collapse. Genetic and pharmacological modulation of PP2Ac and STEAP3, including the use of okadaic acid to inhibit PP2A and pifithrin-alpha to block p53, supported this regulatory axis, and chromatin immunoprecipitation combined with quantitative PCR and dual-luciferase reporter assays confirmed that p53 directly controls STEAP3 transcription.

The findings position CDCA5 as both a biomarker and a functional target. Because elevated CDCA5 correlates with poor prognosis in hepatocellular carcinoma, measuring the protein could help clinicians stratify patients. More intriguingly, the study suggests that pharmacologically disrupting the PP2Ac–p53–STEAP3 axis could restore ferroptotic vulnerability in liver tumors that currently resist this form of cell death. Such an approach would not directly kill cancer cells but would instead prime them for destruction by ferroptosis-inducing agents, potentially offering a combination strategy for hepatocellular carcinoma, a cancer with limited treatment options once it advances beyond surgical resection.

The researchers caution that the pan-cancer correlations between CDCA5 and genomic instability, immune infiltration, and drug response remain primarily correlative and require further validation. The mechanistic work, however, is supported by multiple independent lines of evidence, including rescue experiments, proteomics, and in vivo xenograft models. Because CDCA5 is essential for sister chromatid cohesion and normal cell-cycle progression, any therapeutic strategy targeting it must account for its role in healthy dividing cells, raising the possibility that selective disruption of the ferroptosis-related branch of its function, rather than the protein itself, may prove safer.

For a cancer that remains one of the leading causes of cancer-related death worldwide, the identification of a new regulatory route controlling ferroptosis resistance is a significant step. The study adds CDCA5, better known as Sororin, to a growing list of cell-cycle proteins that moonlight in tumor metabolism, and it highlights the PP2Ac–p53–STEAP3 axis as a potential entry point for restoring ferroptotic sensitivity in hepatocellular carcinoma. As researchers continue to decode how tumors evade iron-driven cell death, this work offers both a mechanistic explanation and a promising therapeutic direction.

Subject of Research: Cell Biology & Cancer

Article Title: CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling

Article References: Wu, D., Zhou, H., Liu, S., Wu, H., Jin, Y., Xing, R., Yang, H., & Wu, G. (2026). CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling. Scientific Reports. https://doi.org/10.1038/s41598-026-74749-0

Image Credits: AI Generated

DOI: 10.1038/s41598-026-74749-0

Keywords: CDCA5, promotes, hepatocellular, carcinoma, progression, suppressing, ferroptosis, PP2Ac, STEAP3, signaling, scientific research

The study, published in Epigenetics Communications, took advantage of a rare and precious resource: cerebrospinal fluid, the clear liquid that bathes the brain and spinal cord, collected day after day from patients fighting for their lives in a neurovascular intensive care unit. Because cerebrospinal fluid is drained as part of routine clinical management to relieve pressure inside the skull after a hemorrhage, the researchers could sample a tissue that sits in intimate contact with the injured brain — something that blood tests simply cannot offer. From 260 patients, they generated longitudinal, genome-wide DNA methylation data spanning 13 days after the bleed, then validated their findings in an independent group of 100 patients.

DNA methylation is a chemical modification in which small methyl groups are attached to specific positions in the DNA sequence, typically dampening the activity of nearby genes. It is a master regulator of how the same genetic blueprint produces neurons, immune cells, and everything else in the body, and it is known to influence brain function, plasticity, and recovery after injury. The Pittsburgh team focused on 36 candidate genes involved in iron homeostasis, the body’s system for managing iron — a logical target because a ruptured aneurysm dumps hemoglobin-rich blood into the cerebrospinal fluid, where heme is broken down to release free, unbound ferrous iron. That free iron is dangerous: it fuels a distinctive form of iron-dependent cell death called ferroptosis, which has been implicated in secondary brain injury after hemorrhagic stroke in animal models.

To make sense of the longitudinal data, the researchers employed group-based trajectory analysis, an unsupervised clustering method that sorts patients into groups sharing similar patterns of change over time. Rather than estimating a single average trajectory for the whole sample, the technique asks whether the population is actually composed of distinct subgroups, each with its own methylation course. Crucially, the team automated the modeling procedure with a predefined decision tree, removing the subjective, iterative choices that traditionally plague this kind of analysis. Of 637 methylation sites examined across the candidate genes, 183 sites in 33 genes yielded reliable trajectory groups and were carried forward for association testing against patient outcomes.

One site towered above the rest: cg25713625, a methylation position within the STEAP3 gene, which encodes a metalloreductase responsible for converting stable, insoluble ferric iron into its more reactive, soluble ferrous form. In the discovery sample, patients whose methylation at this site fell into the highest trajectory group faced dramatically worse odds than those in the lowest group. The odds of an unfavorable outcome on the Glasgow Outcome Scale — a measure of functional recovery — were 11.7 times higher at three months and 15.6 times higher at twelve months. The odds of death were 19.1 times higher at three months and 12.8 times higher at twelve months, all meeting the study’s empirical thresholds for statistical significance.

What makes these findings compelling is that they replicated. In the independent sample of 100 patients, the same trajectory structure emerged, and the associations held: an 8.2-fold increase in odds of unfavorable recovery at three months, a 6.3-fold increase at twelve months, and a 2.3-fold increase in the odds of death at three months, with a suggestive association for death at twelve months. The effect was additive — with each step up in methylation trajectory group, the proportion of patients with poor outcomes climbed steeply. In the replication sample, not a single patient in the lowest methylation group had an unfavorable Glasgow Outcome Scale score at three months, compared with 61.5 percent of those in the highest group.

Biologically, the result makes unsettling sense. STEAP3 is essential for normal iron handling — its deficiency causes microcytic anemia with iron overload — but in the aftermath of a hemorrhage, its activity may become a liability. By converting ferric iron to the ferrous form, STEAP3 potentially increases the pool of reactive iron available to drive lipid peroxidation, the oxidative destruction of cell membranes that lies at the heart of ferroptosis. Animal studies support this logic: elevated iron after experimental subarachnoid hemorrhage raises lipid peroxide levels, and ferrostatin-1, a lipophilic antioxidant that shields membranes from lipid oxidation, reduces free iron and prevents both ferroptosis and early brain injury in those models. STEAP3 has also been linked to p53-mediated apoptosis and to immune function, and it is the only member of the STEAP family highly expressed in macrophages. Intriguingly, previous work found STEAP3 to be more than 2.5-fold overexpressed in the walls of unruptured intracranial aneurysms compared with control artery tissue.

Two other candidate genes told a more cautionary tale. A methylation site in the amyloid precursor protein gene, APP, which participates in iron efflux by stabilizing ferritin and ferroportin, showed promising associations with favorable outcomes and survival in the discovery phase, but the trajectory structure failed to replicate. A dynamic site in the inflammatory cytokine gene TNF, which sits within a hotspot of outcome-associated methylation positions, also failed replication. Only the STEAP3 signal survived independent testing, underscoring how easily early findings in epigenetic studies can dissolve under scrutiny — and how valuable embedded replication is for distinguishing robust signals from statistical noise.

Perhaps the most clinically surprising observation was that methylation at the STEAP3 site barely changed over the 13-day monitoring window. The trajectories were largely flat, suggesting that a single early measurement might capture the same predictive information as repeated sampling. Post hoc cross-sectional analyses confirmed persistent associations between continuous methylation levels and long-term outcomes at multiple time points from days 3 through 11 after the hemorrhage. The association also survived adjustment for cell type heterogeneity — the shifting mixture of blood, brain, and vessel cells that contaminates cerebrospinal fluid after a bleed — which strengthens the case that the signal reflects genuine biology rather than changing cellular composition. One caveat: methylation at the site showed only a small to moderate correlation between blood and cerebrospinal fluid, indicating that a simple blood test would likely not substitute for the brain-proximal fluid.

The researchers are careful to frame this as a first step rather than a finished clinical tool. The study population was predominantly composed of participants who self-identified as White, limiting generalizability, and the candidate gene approach, though rigorously corrected for multiple testing, may have missed signals in genes that could not be reliably modeled, including two iron homeostasis genes on the X chromosome that were excluded during quality control. Functional studies are needed to determine whether methylation at cg25713625 actually alters STEAP3 activity and ferroptosis in the injured brain, or whether it merely marks some deeper vulnerability. Still, the prospect is tantalizing: a methylation marker measurable in fluid already being drained from patients could one day help clinicians identify, within days of a devastating hemorrhage, who needs the most aggressive monitoring — and it could spotlight iron metabolism, and ferroptosis in particular, as a target for therapies that might finally move the needle on outcomes in this brutal disease.

Subject of Research: DNA methylation of the iron homeostasis gene STEAP3 in cerebrospinal fluid as a predictor of outcomes after aneurysmal subarachnoid hemorrhage

Article Title: Iron homeostasis pathway DNA methylation trajectories reveal a role for STEAP3 metalloreductase in patient outcomes after aneurysmal subarachnoid hemorrhage

Article References: Heinsberg, L. W., Weeks, D. E., Alexander, S. A., Minster, R. L., Sherwood, P. R., Poloyac, S. M., Deslouches, S., Crago, E. A., & Conley, Y. P. (2021). Iron homeostasis pathway DNA methylation trajectories reveal a role for STEAP3 metalloreductase in patient outcomes after aneurysmal subarachnoid hemorrhage. Epigenetics Communications, 1(1), Article 4. https://doi.org/10.1186/s43682-021-00003-5

Image Credits: AI Generated

DOI: 10.1186/s43682-021-00003-5

Keywords: aneurysmal subarachnoid hemorrhage, DNA methylation, STEAP3, iron homeostasis, ferroptosis, cerebrospinal fluid, epigenetics, biomarker, stroke, group-based trajectory analysis, lipid peroxidation, Glasgow Outcome Scale